• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗前列腺癌的人源化/去免疫抗前列腺特异性膜抗原免疫毒素的评估

Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer.

作者信息

Michalska Marta, Schultze-Seemann Susanne, Kuckuck Irina, Wolf Philipp

机构信息

Department of Urology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Department of Urology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

出版信息

Anticancer Res. 2018 Jan;38(1):61-69. doi: 10.21873/anticanres.12192.

DOI:10.21873/anticanres.12192
PMID:29277757
Abstract

BACKGROUND

We generated humanized/de-immunized immunotoxins targeting the prostate-specific membrane antigen (PSMA) and tested their cytotoxic activity against prostate cancer cells in vitro.

MATERIALS AND METHODS

The humanized/de-immunized version of our murine anti-PSMA single-chain antibody fragment (scFv) D7, termed hD7-1(VL-VH), was ligated to the 40-kDa toxin domain of Pseudomonas aeruginosa exotoxin A (PE40), and to the deimmunized 24-kDa toxin domains PE24 or PE24mut. The immunotoxins designated as hD7-1(VL-VH)-PE40, hD7-1(VL-VH)-PE24 and hD7-1(VL-VH)-PE24mut were bacterially expressed and purified by affinity chromatography. Binding and cytotoxicity were examined by flow cytometry and viability assay, respectively.

RESULTS

All immunotoxins revealed strong binding to prostate cancer cells expressing PSMA and specific cytotoxicity, with half-maximal inhibitory concentration values in the picomolar range.

CONCLUSION

We successfully created powerful anti-PSMA immunotoxins with reduced immunogenicity for further clinical development and application against advanced prostate cancer.

摘要

背景

我们制备了靶向前列腺特异性膜抗原(PSMA)的人源化/去免疫化免疫毒素,并在体外测试了它们对前列腺癌细胞的细胞毒活性。

材料与方法

将我们的鼠抗PSMA单链抗体片段(scFv)D7的人源化/去免疫化版本,即hD7-1(VL-VH),与铜绿假单胞菌外毒素A(PE40)的40 kDa毒素结构域,以及去免疫化的24 kDa毒素结构域PE24或PE24mut连接。命名为hD7-1(VL-VH)-PE40、hD7-1(VL-VH)-PE24和hD7-1(VL-VH)-PE24mut的免疫毒素通过细菌表达,并通过亲和层析进行纯化。分别通过流式细胞术和活力测定来检测结合和细胞毒性。

结果

所有免疫毒素均显示出与表达PSMA的前列腺癌细胞有强结合及特异性细胞毒性,半数最大抑制浓度值在皮摩尔范围内。

结论

我们成功制备了免疫原性降低的强效抗PSMA免疫毒素,用于进一步的临床开发及针对晚期前列腺癌的应用。

相似文献

1
Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer.用于治疗前列腺癌的人源化/去免疫抗前列腺特异性膜抗原免疫毒素的评估
Anticancer Res. 2018 Jan;38(1):61-69. doi: 10.21873/anticanres.12192.
2
Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.抗前列腺特异性膜抗原单链免疫毒素对前列腺癌的临床前评价。
J Immunother. 2010 Apr;33(3):262-71. doi: 10.1097/CJI.0b013e3181c5495c.
3
Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer.结构变异对靶向前列腺癌的抗 PSMA scFv 和免疫毒素生物活性的影响。
Anticancer Res. 2010 Sep;30(9):3373-9.
4
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.PI3K抑制剂ZSTK474与靶向PSMA的免疫毒素联合使用可加速前列腺癌的细胞凋亡和消退。
Neoplasia. 2013 Oct;15(10):1172-83. doi: 10.1593/neo.13986.
5
Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.抗前列腺特异性膜抗原免疫毒素作为前列腺癌的新型治疗方法?对SCID小鼠人前列腺异种移植肿瘤具有高特异性抗肿瘤活性。
Prostate. 2008 Feb 1;68(2):129-38. doi: 10.1002/pros.20684.
6
Enhanced cytotoxicity of a Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861.通过添加内体逃逸增强剂SO1861增强基于外毒素A的免疫毒素对前列腺癌的细胞毒性。
Front Pharmacol. 2023 Jul 6;14:1211824. doi: 10.3389/fphar.2023.1211824. eCollection 2023.
7
A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.一种重组的前列腺特异性膜抗原(PSMA)单链免疫毒素对前列腺癌细胞具有强大且选择性的毒性。
Cancer Immunol Immunother. 2006 Nov;55(11):1367-73. doi: 10.1007/s00262-006-0131-0. Epub 2006 Mar 18.
8
Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.联合前列腺癌特异性免疫毒素与 BH3 模拟物 ABT-737 的协同细胞毒性。
Cancer Immunol Immunother. 2018 Mar;67(3):413-422. doi: 10.1007/s00262-017-2097-5. Epub 2017 Nov 29.
9
Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.包含与铜绿假单胞菌外毒素融合的单克隆抗体B3的VH或VL结构域的重组免疫毒素。
J Immunol. 1993 Apr 1;150(7):2774-82.
10
Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.一种针对人及小鼠前列腺特异性膜抗原的免疫毒素对小鼠的抗肿瘤作用及无副作用情况
Prostate. 2004 Sep 15;61(1):1-11. doi: 10.1002/pros.20074.

引用本文的文献

1
Enhanced cytotoxicity of a Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861.通过添加内体逃逸增强剂SO1861增强基于外毒素A的免疫毒素对前列腺癌的细胞毒性。
Front Pharmacol. 2023 Jul 6;14:1211824. doi: 10.3389/fphar.2023.1211824. eCollection 2023.
2
Recombinant immunotoxins development for HER2-based targeted cancer therapies.用于基于HER2的靶向癌症治疗的重组免疫毒素研发。
Cancer Cell Int. 2021 Sep 6;21(1):470. doi: 10.1186/s12935-021-02182-6.
3
Targeted Toxins for the Treatment of Prostate Cancer.
用于治疗前列腺癌的靶向毒素
Biomedicines. 2021 Aug 9;9(8):986. doi: 10.3390/biomedicines9080986.
4
PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model.PSMA导向的嵌合抗原受体T细胞联合低剂量多西他赛治疗在前列腺癌异种移植模型中诱导肿瘤消退。
Mol Ther Oncolytics. 2020 Jun 24;18:226-235. doi: 10.1016/j.omto.2020.06.014. eCollection 2020 Sep 25.
5
Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer.前列腺特异性膜抗原识别的结构基础 A9g RNA 适体。
Nucleic Acids Res. 2020 Nov 4;48(19):11130-11145. doi: 10.1093/nar/gkaa494.
6
identification and modification of T cell epitopes in pertussis antigens associated with tolerance.鉴定和修饰与耐受相关的百日咳抗原中的 T 细胞表位。
Hum Vaccin Immunother. 2020;16(2):277-285. doi: 10.1080/21645515.2019.1703453. Epub 2020 Jan 17.
7
Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity.抗药物抗体:预测、降低或逆转生物治疗性免疫原性的新方法
Antibodies (Basel). 2018 May 31;7(2):19. doi: 10.3390/antib7020019.
8
Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.人源单克隆 PSMA 抗体介导的 TRIM24 siRNA 递送在 PSMA 阳性去势抵抗性前列腺癌中的治疗效果。
Theranostics. 2019 Feb 7;9(5):1247-1263. doi: 10.7150/thno.29884. eCollection 2019.